Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.06 USD | +0.72% | -0.99% | -12.21% |
May. 20 | Exelixis Settles Cabometyx Patent Litigation with Cipla | MT |
May. 14 | Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM |
Evolution of the average Target Price on Exelixis, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Exelixis, Inc.
Stephens Inc. | |
RBC Capital Markets | |
Barclays | |
BTIG | |
Citigroup | |
Guggenheim | |
JMP Securities | |
Oppenheimer | |
SVB Securities LLC | |
Morgan Stanley | |
Wells Fargo Securities | |
Credit Suisse | |
EF Hutton | |
Truist Securities | |
Piper Sandler | |
BMO Capital | |
Jefferies & Co. | |
HC Wainwright | |
Needham & Co. | |
Goldman Sachs | |
Wolfe Research |
EPS Revisions
- Stock Market
- Equities
- EXEL Stock
- Consensus Exelixis, Inc.